However, numerousstudies have indicated that resistance to dabrafenib monotherapy can develop viasecondary genetic alterations and expression, increasing MAPK signaling andcontinued cancer growth (36).Another observation of dabrafenib monotherapy was that a large number of patientswere diagnosed with secondary skin cancers, which were associated with contradictoryactivation of the MAPK pathway in nonmutant BRAF cells (37). This evidence concerns the gene BRAF and skin cancer.